Skip to content

Efficacy and safety of esketamine combined with propofol-remifentanil sedation during painless gastroenteroscopy

Efficacy and safety of esketamine combined with propofol-remifentanil sedation during painless gastroenteroscopy

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400079866
Enrollment
Unknown
Registered
2024-01-15
Start date
2024-01-25
Completion date
Unknown
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia

Interventions

esketamine 1 group:esketamine 0.05mg/kg/h
esketamine 2 group:esketamine 0.1mg/kg/h
esketamine 3 group:esketamine 0.15mg/kg/h

Sponsors

Huai’an First People’s Hospital of Nanjing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.Patients undergoing gastroenteroscopy. 2.American Society of Anesthesiologists (ASA) Class I - II patients. 3.Patients aged 20-65 years, BMI=30%.

Exclusion criteria

Exclusion criteria: 1.Patients with abnormal liver and kidney function tests or electrolyte disorders. 2.Patients received antidepressant, sedative and analgesic drugs within two weeks before surgery. 3.Patients with contraindications to use related drugs. 4.Patients with myocardial infarction, poorly controlled hypertension (systolic blood pressure > 180mmHg), cerebrovascular disease. 5.Language or body dysfunctions who could not cooperate to complete the scales. 6.Patients with sleep apnea syndrome.

Design outcomes

Primary

MeasureTime frame
somatic responses;blood pressure;Pulse oxygen;heart rate;

Secondary

MeasureTime frame
Mini-mental State Examination;Montreal Cognitive Assessment ;recovery time;Time to leave the recovery room;

Countries

China

Contacts

Public ContactLijun An

Huai’an First People’s Hospital of Nanjing Medical University

hayyalj@njmu.edu.cn+86 138 6155 9992

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026